Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Post-stroke Neural Plasticity With Atomoxetine
- Conditions
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Lumy Sawaki
- Target Recruit Count
- 12
- Registration Number
- NCT02788357
Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT02784535
- Locations
- 🇺🇸
Dysautonomic Center at NYU Langone Medical Center, New York, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers
- Conditions
- Interventions
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Seoul National University Childrens Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02623114
- Locations
- 🇰🇷
Seoul National University Children's Hospital, Seoul, Korea, Republic of
Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 57
- Registration Number
- NCT02500732
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
EAA/Therapy for Treating Children With ADHD
- Conditions
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT02482649
- Locations
- 🇰🇷
Yoo-Sook Joung, Seoul, Korea, Republic of
Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 600
- Registration Number
- NCT02430896
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Effects of Atx and Oros-mph on Executive Functions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- TC Erciyes University
- Target Recruit Count
- 43
- Registration Number
- NCT02352051
Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Yale University
- Registration Number
- NCT02046551
- Locations
- 🇺🇸
West Haven Veterans Affairs, West Haven, Connecticut, United States
Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 41
- Registration Number
- NCT02014064
Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Yale University
- Target Recruit Count
- 90
- Registration Number
- NCT01863251
- Locations
- 🇲🇾
Universiti Sains Malaysia, Kota Bharu, Malaysia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.